@article{d08e769ab2f94d70b3cd190b410701a4,
title = "Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup.",
abstract = "BACKGROUND: Survivors of childhood cancers are at risk of developing subsequent primary leukaemias (SPLs), but the long-term risks beyond 20 years of treatment are still unclear. We investigated the risk of SPLs in five-year childhood cancer survivors using a large-scale pan-European (PanCareSurFup) cohort and evaluated variations in the risk by cancer and demographic factors. METHODS: This largest-ever assembled cohort comprises 69,460 five-year childhood cancer survivors from 12 European countries. Standardised incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. RESULTS: One hundred fifteen survivors developed an SPL including 86 myeloid leukaemias (subsequent primary myeloid leukaemias [SPMLs]), 17 lymphoid leukaemias and 12 other types of leukaemias; of these SPLs, 31 (27%) occurred beyond 20 years from the first childhood cancer diagnosis. Compared with the general population, childhood cancer survivors had a fourfold increased risk (SIR = 3.7, 95% confidence interval [CI]: 3.1 to 4.5) of developing leukaemia, and eight leukaemias per 100,000 person-years (AER = 7.5, 95% CI: 6.0 to 9.2) occurred in excess of that expected. The risks remained significantly elevated beyond 20 years from the first primary malignancy (SIR = 2.4, 95% CI: 1.6 to 3.4). Overall, the risk ratio for SPML (SIR = 5.8, 95% CI: 4.6 to 7.1) was higher than that for other SPLs. CONCLUSIONS: We demonstrate that beyond 20 years after childhood cancer diagnosis, survivors experience an increased risk for SPLs compared with that expected from the general population. Our findings highlight the need for awareness by survivors and their healthcare providers for potential risk related to SPL.",
keywords = "Childhood cancer survivors, Lymphoid leukaemias, Myeloid leukaemias, Second cancers, Subsequent primary leukaemia, Krabbamein, Hv{\'i}tbl{\ae}{\dh}i, B{\"o}rn, Fylgikvillar, Leukemia, Neoplasms, Second Primary, Cancer Survivors, Childhood cancer survivors, Lymphoid leukaemias, Myeloid leukaemias, Second cancers, Subsequent primary leukaemia, Krabbamein, Hv{\'i}tbl{\ae}{\dh}i, B{\"o}rn, Fylgikvillar, Leukemia, Neoplasms, Second Primary, Cancer Survivors",
author = "Allodji, {Rodrigue S} and Hawkins, {Mike M} and Bright, {Chloe J} and Fidler-Benaoudia, {Miranda M} and Winter, {David L} and Daniela Alessi and Brice Fresneau and Neige Journy and Vera Morsellino and Edit B{\'a}rdi and Andrea Bautz and Julianne Byrne and Feijen, {Elizabeth Lieke Am} and Teepen, {Jop C} and Giao Vu-Bezin and Carole Rubino and Stanislaw Garwicz and Desiree Grabow and Thorgerdur Gudmundsdottir and Joyeeta Guha and Eva-Maria Hau and Momcilo Jankovic and Peter Kaatsch and Melanie Kaiser and Helena Linge and Monica Muraca and Damien Llanas and Cristina Veres and Hilde {\O}fstaas and Ibrahima Diallo and Imene Mansouri and Ronckers, {Cecile M} and Roderick Skinner and Monica Terenziani and Finn Wesenberg and Thomas Wiebe and Carlotta Sacerdote and Zsuzsanna Jakab and Riccardo Haupt and P{\"a}ivi L{\"a}hteenm{\"a}ki and Zaletel, {Lorna Zadravec} and Kuehni, {Claudia E} and Winther, {Jeanette F} and Gisela Michel and Kremer, {Leontien C M} and Lars Hjorth and Nadia Haddy and {De Vathaire}, Florent and Reulen, {Raoul C}",
year = "2019",
month = aug,
doi = "10.1016/j.ejca.2019.05.013",
language = "English",
journal = "European Journal of Cancer",
issn = "1879-0852",
publisher = "Elsevier Ltd.",
}